-
-
-
-
-
-
-
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
-
-
-
-
-
-
-
HUTCHMED (China) (HCM) Receives $15M Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS in Lung Cancer
-
-
-
-
-
-
-
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
-
-
-
-
-
-
64,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

